Novartis reported Phase 3 results showing GanLum (ganaplacide + lumefantrine) achieved non‑inferiority to current standard therapy and cleared World Health Organization efficacy thresholds in trials across sub‑Saharan Africa. The multi‑center study enrolled roughly 1,688 adults and children and showed cure rates at or above the 95% WHO target in key analyses, and evidence of transmission blocking and activity against resistant parasites was presented at ASTMH. Novartis said it will seek regulatory approvals “as soon as possible” and highlighted the drug’s novel mechanism—ganaplacide disrupts parasite protein transport—positioning GanLum as the first genuinely new antimalarial in over 25 years. The data matter for endemic countries facing rising artemisinin resistance and for global health groups planning treatment policy updates.